0.2653
Precedente Chiudi:
$0.2666
Aprire:
$0.284
Volume 24 ore:
401.87K
Relative Volume:
0.25
Capitalizzazione di mercato:
$62.81M
Reddito:
$175.04M
Utile/perdita netta:
$-44.52M
Rapporto P/E:
-1.4739
EPS:
-0.18
Flusso di cassa netto:
$-56.05M
1 W Prestazione:
+11.59%
1M Prestazione:
+6.32%
6M Prestazione:
-63.96%
1 anno Prestazione:
-74.92%
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Nome
Adaptimmune Therapeutics Plc Adr
Settore
Industria
Telefono
44 1235 430000
Indirizzo
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Confronta ADAP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.2655 | 62.81M | 175.04M | -44.52M | -56.05M | -0.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
491.67 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
598.60 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
610.98 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
249.64 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
246.35 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-07-30 | Iniziato | H.C. Wainwright | Buy |
2024-05-30 | Iniziato | Scotiabank | Sector Outperform |
2023-03-24 | Iniziato | Bryan Garnier | Buy |
2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-11-09 | Aggiornamento | Mizuho | Neutral → Buy |
2021-05-28 | Iniziato | Barclays | Underweight |
2020-04-22 | Iniziato | Mizuho | Neutral |
2019-08-02 | Downgrade | Guggenheim | Buy → Neutral |
2019-05-31 | Iniziato | ROTH Capital | Buy |
2019-05-30 | Ripresa | Citigroup | Buy |
2019-05-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2017-03-17 | Iniziato | Wells Fargo | Market Perform |
2016-10-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
2016-09-30 | Iniziato | Raymond James | Outperform |
2016-02-25 | Iniziato | Citigroup | Buy |
2015-06-01 | Iniziato | BofA/Merrill | Neutral |
2015-06-01 | Iniziato | Guggenheim | Buy |
2015-06-01 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile
Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex
Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India
Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa
Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com
Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com
Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639 - Investing.com
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Adaptimmune Therapeutics Plc Adr Azioni (ADAP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adaptimmune Therapeutics Plc Adr Azioni (ADAP) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Lunger John | Chief Patient Supply Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
Bertrand William C JR | Chief Operating Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '25 |
Sale |
0.58 |
30,601 |
17,773 |
44,327 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):